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Study Objective. To identify the factors associated with newly prescribed,
first-line, second-generation antipsychotics (SgAs) associated with weight
gain—olanzapine, risperidone, and quetiapine.
Design. Retrospective medical record review.
Setting. Outpatient and inpatient psychiatry services at a tertiary care,
academic medical center.
Patients. Three hundred forty consecutive adults who had major depressive
disorder with psychotic features, bipolar I, bipolar II, bipolar not otherwise
specified, or schizoaffective disorder over two time periods (August
30–October 30, 2009, and April 1–May 31, 2010).
Measurements and Main Results. Clinical and sociodemographic variables
associated with newly prescribed olanzapine, risperidone, and quetiapine
were identified by using univariate and multivariate logistic regression.
Several clinical factors were individually associated with initiation of these
SgAs:  mania (odds ratio [OR] 3.6, 95% confidence interval [CI] 1.2–10.8,
p=0.02), psychosis (OR 3.3, 95% CI 1.5–6.9, p=0.002), and inpatient
treatment (OR 3.8, 95% CI 1.8–7.9, p=0.0005).  Prevalent use of lithium
(OR 0.3, 95% CI 0.1–0.9, p=0.03) and being married (OR 0.3, 95% CI
0.1–0.8, p=0.02) were inversely associated with new use of an SgA.  Mania,
psychosis, married status, and lithium use remained independently
associated on multivariate analysis.  Factors related to metabolic or vascular
risk were not associated with SgA initiation.
Conclusion. Psychiatric clinicians were influenced heavily by clinical features
related to mental status and acuity when determining whether to prescribe
SgAs.  However, factors related to vascular risk were not associated.  Future
observational studies should consider current clinical status as an important
factor in determining propensity to receive antipsychotics or other short-
term treatments for bipolar and related disorders.
Key Words: antipsychotic agents, bipolar disorder, inpatients, logistic models,
major depressive disorder, outpatients, propensity score, psychotic disorders.
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Second-generation antipsychotics (SgAs) are
commonly prescribed for the treatment of bipolar
disorders.1, 2 Despite the reduced propensity for
extrapyramidal symptoms compared with first-
generation antipsychotics3, 4—especially high-
potency first-generation antipsychotics5—SgAs
have increasingly been associated with significant
metabolic complications such as the metabolic
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syndrome and its components of dyslipidemia,
insulin resistance, and obesity.6, 7 The SgAs
produce variable weight gain, greatest for
clozapine and olanzapine, followed by quetiapine
and risperidone.8 Clozapine tends to be reserved
for treatment-refractory cases because of its
adverse-effect profile and subsequent need for
routine laboratory monitoring.  The Clinical
Antipsychotic Trials of Intervention Effectiveness
(CATIE) schizophrenia trial found that change in
Framingham-calculated 10-year coronary heart
disease risk differed most among agents for
participants who were at highest vascular disease
risk at the outset of antipsychotic treatment.9
Although not reflected in practice guidelines for
bipolar disorder,10 existing data support
antipsychotic selection based on impact on
vascular disease risk factors, and the American
Diabetes Association and American Psychiatric
Association consensus statement recommends “it
may be preferable to initiate treatment with an
SgA that appears to have a lower propensity for
weight gain or glucose intolerance” for at-risk
patients.7
With regard to vascular disease outcomes, a
meta-analysis of clinical trials of antipsychotics
in patients with dementia or related conditions
found increased cerebrovascular events in those
assigned antipsychotics.11 Due to the infrequency
of vascular events in younger populations, data
linking antipsychotics to vascular outcomes are
limited to large, pharmacoepidemiologic studies.12–16
However, these studies are sensitive to confounding
by indication, and key confounders, such as
presenting clinical symptoms, health behaviors,
and body mass index, may be unavailable in
administrative claims databases.  Unfortunately,
there is a paucity of data regarding the determinants
of antipsychotic prescribing in patients with
bipolar and related disorders.1, 2 Information
about the clinical features associated with
initiation of specific SgAs may be useful in the
design and interpretation of such studies.
We sought to determine which patients from a
clinical sample of outpatients and inpatients with
diagnoses of a bipolar or related affective disorder
are most likely to be prescribed the three first-
line SgAs with greater propensity for causing
weight gain:  risperidone, olanzapine, and
quetiapine.  Our primary hypotheses were that
patients prescribed these SgAs would be more
likely to have manic or psychotic symptoms and
less likely to have risk factors for vascular disease
compared with the remainder of the sample not
prescribed these drugs.
Methods
This retrospective medical record review was
approved by the University of Iowa institutional
review board.  All consecutive patients aged 18
years or older with an encounter that included
primary medical record diagnosis of a bipolar or
related affective disorder including bipolar I,
bipolar II, bipolar not otherwise specified,
schizoaffective disorder (bipolar subtype), and
major depressive disorder with psychotic features
during August 30–October 30, 2009, and April
1–May 31, 2010, were included.  These disorders
have been considered to represent a spectrum of
related conditions.17–19 To maintain as represen-
tative a clinical sample as possible, no other
inclusion or exclusion criteria were applied.
We identified individuals who were newly
prescribed an SgA associated with weight gain—
risperidone, olanzapine, or quetiapine—during a
visit during these two time windows.  New users
could have been taking a different antipsychotic
at the time the SgA was started.  Based on the
psychiatric clinician’s written notes for the first
visit at which one of these drugs was prescribed,
we determined whether this was a new SgA user,
which will be referred to throughout this article
as a new user of risperidone, olanzapine, or
quetiapine.  The comparison (control) group was
composed of all other individuals.  In the case of
multiple visits, only one visit was abstracted:  the
visit at which SgA was started or, for those who
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did not start SgAs, the last visit in the study
period.  Clinical and sociodemographic variables
were abstracted to assess differences between
new users of SgAs and all other individuals.
Age, sex, race or ethnicity, marital status, and
insurance were obtained from the electronic
hospital records.  Type of insurance was classified
as private, public, or none.  Clinical features of
the disorder were abstracted from the index visit
narrative and mental status examination in the
following categories:  depressed, manic, psychotic,
and suicidal.  Active substance abuse was also
noted.  Measures of weight and body mass index
were obtained from the records for each visit or
the most recent prior visit when not available.
Obesity was determined from a medical record
diagnosis or body mass index of 30 or higher.
The presence of hypertension or diabetes mellitus
was determined by medical record diagnosis of or
treatment for the respective condition.  These
diagnoses were not inferred from vital signs or
laboratory values.  Psychotropic drugs and any
new prescriptions for SgAs were recorded.  New
use was noted irrespective of current or recent
drugs.
Statistical Analysis
All statistical analyses were performed by using
SAS software, version 9.2 (SAS Institute Inc.,
Cary, NC).  The study demonstrated 81% power
to detect a medium effect size of 0.5 standard
deviations for continuous variables.  Descriptive
statistics were generated.  Univariate analyses
assessed the association of new use of SgAs with
the abstracted clinical and sociodemographic
variables.  Independent samples t tests and 2
tests were applied to identify associations
between continuous and categoric variables,
respectively, by new use of SgAs.
With new SgA use as the dependent outcome
variable of interest, logistic regression models
were explored to find the most useful multi-
variate model.  The following independent
variables were considered:  age; sex; race
(Caucasian or non-Caucasian); marital status
(married or not married); insurance type;
inpatient setting; prevalent use of lamotrigine,
lithium, valproic acid, or antipsychotics; suicidal
ideation; psychosis; depression; mania; active
substance abuse; diagnosis or treatment of
diabetes; diagnosis or treatment of hypertension;
and obesity.  given the correlation of certain
independent variables considered, stepwise
procedures were deferred.  Model selection began
with significant variables from univariate
analyses and sought a plausible model that
minimized the Schwarz information criterion,
which was selected over the Akaike information
criterion to reduce the risk of overfitting by
imposing a greater penalty for the number of
model parameters.20 Continuous variables were
assessed for possible nonconformity to a linear
gradient.  Interactions were considered.  goodness
of fit was assessed with use of the Hosmer-
Lemeshow statistic.
Results
From a total of 735 inpatient and outpatient
psychiatry visits for 340 patients, 36 (11%) new
users of the three first-line SgAs associated with
weight gain (risperidone, olanzapine, quetiapine)
were identified in the two periods sampled.  The
remaining 304 patients served as the comparison
(control) group.  As shown in Table 1, the mean
± SD age of all participants was 46.4 ± 15.9 years.
Approximately one third (34%) of diagnoses in
this sample were for bipolar I.  With regard to
clinical features, 17% of the patients had some
evidence of psychosis, 19% were depressed, 5%
were manic, and 6% were suicidal.  Nearly half of
the patients (42%) were obese.  Other clinical
and sociodemographic characteristics of this
sample are outlined in Table 1.
In univariate logistic regression, the presence
of mania (odds ratio [OR] 3.6, 95% confidence
interval [CI] 1.2–10.8, 2=5.28, df=1, p=0.02),
psychotic symptoms (OR 3.3, 95% CI 1.5–6.9,
2=9.50, df=1, p=0.002), and treatment in an
inpatient setting (OR 3.8, 95% CI 1.8–7.9,
2=12.22, df=1, p=0.0005) were associated with
new use of an SgA.  Prevalent use of lithium (OR
0.3, 95% CI 0.1–0.9, 2=4.80, df=1, p=0.03) and
being married (OR 0.3, 95% CI 0.1–0.8, 2=5.22,
df=1, p=0.02) were inversely associated with new
use of an SgA.  Other clinical and socio-
demographic variables were not significantly
associated with the initiation of SgAs, including
obesity (OR 1.3, 95% CI 0.6–2.6, 2=0.40, df=1,
p=0.52), hypertension (OR 0.5, 95% CI 0.2–1.4,
2=1.71, df=1, p=0.19), and diabetes (OR 0.6,
95% CI 0.2–2.2, 2=0.45, df=1, p=0.50).
The optimal multivariate model included
prevalent lithium use, mania, married status, and
psychosis, as shown in Table 2.  The overall
model was significant (likelihood ratio 2=25.92,
df=4, p<0.0001) and demonstrated goodness-of-
fit (Hosmer-Lemeshow 2=2.46, df=4, p=0.65)
with an area under the curve of 0.77 (95% CI
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with Weight gain Controls All Patients
Characteristic (n=36) (n=304) (n=340)
No (%) of Patients
Female 18 (50) 190 (63) 208 (61)
Race
Caucasian 31 (86) 281 (92) 312 (92)
African-American 1 (3) 7 (2) 8 (2)
Asian 1 (3) 3 (1) 4 (1)
Unknown 2 (6) 7 (2) 9 (3)
Other 1 (3) 6 (2) 7 (2)
Ethnicity
Hispanic or Latino 0 (0) 5 (2) 5 (1)
Primary psychiatric diagnosis
Bipolar I 10 (28) 104 (34) 114 (34)
Bipolar II 5 (14) 55 (18) 60 (18)
Bipolar not otherwise specified 3 (8) 37 (12) 40 (12)
Major depressive disorder 8 (22) 28 (9) 36 (11)
Schizoaffective disorder 10 (28) 80 (26) 90 (26)
Psychotropic drugs
Lithiuma 3 (8) 79 (26) 82 (24)
Valproic acid derivatives 6 (17) 46 (15) 52 (15)
Lamotrigine 3 (8) 51 (17) 54 (16)
Carbamazepine 0 (0) 6 (2) 6 (2)
Antipsychotics
First generation 10 (28) 46 (15) 56 (16)
Second generation 13 (36) 159 (52) 172 (51)
Antidepressants 17 (47) 177 (58) 194 (57)
Benzodiazepines 8 (22) 108 (36) 116 (34)
Clinical features
Psychosisb 13 (36) 45 (15) 58 (17)
Maniaa 5 (14) 13 (4) 18 (5)
Depression 9 (25) 57 (19) 66 (19)
Suicidal ideation 1 (3) 20 (7) 21 (6)
Active substance abuse 6 (17) 22 (7) 28 (8)
Inpatient settingb 14 (39) 44 (15) 58 (17)
Insurance
Public 18 (50) 168 (55) 186 (55)
Private 18 (50) 131 (43) 149 (44)
None 0 (0) 5 (2) 5 (1)
Marital status
Marrieda 4 (11) 92 (30) 96 (28)
Divorced or separated 9 (25) 51 (17) 60 (18)
Single 22 (61) 149 (49) 171 (50)
Widow 1 (3) 11 (4) 12 (4)
Unknown 0 (0) 1 (0.3) 1 (0.3)
Medical diagnosis or treatment
Diabetes mellitus 3 (8) 37 (12) 40 (12)
Hypertension 5 (14) 72 (24) 77 (23)
Obesity 17 (47) 125 (41) 142 (42)
Mean ± SD
Age (yrs) 41.3 ± 15.5 47.0 ± 15.9 46.4 ± 15.9
Weight (kg)c 90.2 ± 25.5 88.5 ± 23.2 88.7 ± 23.5
Body mass index (kg/m2)d 30.9 ± 7.5 30.8 ± 8.0 30.8 ± 7.9
ap<0.05 for comparison of new users versus controls.
bp<0.01 for comparison of new users versus controls.
cData were missing for 8% of patients.
dData were missing for 14% of patients.
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0.70–0.85) on receiver operating characteristic
analysis.
Discussion
The SgAs are a common treatment for bipolar
and related disorders, although it is unclear how
psychiatric clinicians select these drugs in
practice, particularly those agents with a greater
propensity for causing weight gain.  In this
analysis of clinical data from inpatient and
outpatient psychiatric settings at a tertiary care
center, risperidone, olanzapine, and quetiapine
appeared to be more likely started in the presence
of appropriate target symptoms—mania, or
psychosis—especially in the higher acuity
inpatient setting.  These drugs were less likely to
be prescribed to individuals who were married or
taking lithium.  Married status may reflect some
marker of illness severity or function.  Lithium
may reduce risk through mania prophylaxis,21, 22
although similar findings were not seen with
valproic acid or lamotrigine.  Those treated with
lithium may be a select group, with lithium
responders even considered a specific subtype,23
and causal conclusions cannot be made from
these data.
In an analysis of the National Ambulatory
Medical Care Survey, prescription of SgAs was
associated with a diagnosis of manic (OR 10.3,
95% CI 2.0–52.0) or mixed (OR 6.9, 95% CI
1.6–30.1) subtypes.24 Our findings extend these
results beyond a diagnostic subtype to a current
clinical manifestation with mania or psychosis.
In a sample of veterans with bipolar disorder,
African-Americans were more likely than
non–African-Americans to receive first-generation
antipsychotics but not SgAs.2 Our study found
no racial differences, although our sample was
predominantly Caucasian.
Limitations
Potential limitations included the use of
medical record data and generalizability of our
findings due to the tertiary care practice setting
and homogeneous racial-ethnic composition of
the study population.  Medical record diagnoses
for psychiatric conditions were made by faculty
psychiatrists, but they could not be verified by
structured interview.  Presumably, prescribing
patterns were based on the diagnosis made,
mitigating the effect of any misclassification.
Individual diagnoses did not appear to discrimi-
nate for new use of SgAs.  If documentation did
not include a diagnosis of or treatment for
conditions such as hypertension or diabetes,
these conditions were classified as not present.
The potential to underestimate the prevalence of
these conditions could reduce the ability to
identify associations between the presence of
these conditions and prescribing patterns.  The
prevalence of obesity was similarly underestimated
due to missing data.  Our data included current
drugs but lacked a history of previous drug use.
Our sample, consistent with the population of
Iowa, included a preponderance of Caucasian
patients.  This impeded our ability to assess
racial-ethnic differences and may further limit
the generalizability of our findings.  Our sample
also consisted only of those receiving treatment
from psychiatric clinicians and may not reflect
the practice of nonpsychiatric clinicians, who
perhaps consider clinical data differently.  The
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Table 2.  Multivariate Logistic Regression Model for Factors Associated with
New Use of Second-Generation Antipsychotics Associated with Weight Gain in
Bipolar Disorders
Odds Ratio
Factor (95% confidence interval) 2 p Value
Lithium use 0.2 (0.06–0.8) 5.46 0.02
Manic state 5.7 (1.7–19.5) 7.86 0.005
Married status 0.3 (0.09–0.8) 5.08 0.02
Psychosis 2.5 (1.2–5.5) 5.59 0.02
The above variables were included in the selected multivariate regression model.  Additional
variables considered for the model included age, diagnosis, depression, suicidal ideation,
active substance abuse, Caucasian, sex, insurance status, inpatient setting, valproic acid
treatment, diagnosis or treatment for hypertension, diagnosis or treatment for diabetes
mellitus, obesity, and weight or body mass index.  The multivariate logistic regression
equation was as follows:  logit(p) = −2.026 – (1.570 • lithium) + (1.749 • mania) – (1.273 •
married) + (0.935 • psychotic), where a value of 1 indicates the presence and 0 indicates the
absence of the dichotomous variable.
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results also may not generalize to prescribing of
other antipsychotics or mood stabilizers.
Nonetheless, this sample is a naturalistic reflec-
tion of psychiatric practice in a large, tertiary care
hospital, allowing assessment of predictors for
prescribing risperidone, olanzapine, and quetiapine
in a real-world setting, in which the prevalence of
antipsychotic use was consistent with prescribing
data for other samples of patients with bipolar
disorder.2
Our results indicate that clinical variables
related to baseline mental status, many of which
may not be readily available from administrative
claims data, appear to be important predictors of
antipsychotic prescribing akin to antidepressant
prescribing.25 Because of this unavailability, these
predictors may not be incorporated into the
propensity scores used for pharmacoepi-
demiologic studies of outcomes associated with
SgAs.12, 26 Future studies should be aware of this
potential limitation and attempt to capture rele-
vant clinical data when available or to calibrate
propensity scores in a subsample in order to
minimize the risk of residual confounding by
indication.  Clinical data related to metabolic and
vascular risk were not significantly associated
with new use of SgAs associated with weight
gain, although diabetes was uncommon, and the
study was underpowered to detect differences in
variables of low prevalence.  These results are
nonetheless consistent with those from a larger
sample not limited to bipolar disorders, suggesting
that metabolic parameters are not considered in
SgA selection27 according to recommendations.7
This is particularly concerning given that
individuals with bipolar disorders remain at
elevated risk for cardiovascular mortality.28, 29
Conclusion
Prescription of first-line SgAs that have been
associated with weight gain in patients with
bipolar and related affective disorders was
appropriately largely driven by acuity of illness,
as evidenced by inpatient setting, and the
presence of psychotic or manic symptoms.  These
data are useful to understanding the deter-
minants of prescribing and for those developing
propensity score–based approaches to post-
marketing surveillance studies, which should
heed the role clinical presentation plays in
influencing initiation of antipsychotics.
Psychiatric clinicians seem to be especially
influenced by clinical variables related to mental
status.  Future study could assess whether
nonpsychiatric clinicians differentially consider
these clinical variables.
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